PRESS RELEASE

For release on March 3

Efor Accelerates Its International Expansion with Two Acquisitions in the United States and Asia

Specialist in securing and ensuring compliance of pharmaceutical manufacturing sites, the French group is simultaneously strengthening its positions in the United States and Asia, reinforcing its role as a trusted industrial partner to the global Top 20 pharmaceutical, biotech, and medtech companies.

Lyon, March 3, 2026 — Efor announces the acquisition of DynamixE in the United States and No deviation in Singapore. Executed simultaneously, these transactions mark a new phase in the acceleration of its international expansion and reflect a clear ambition: to build a global leader in quality and compliance dedicated to the healthcare industries.

A Strategic Move in Two Key Markets

With these acquisitions, Efor strengthens its presence in the most decisive regions of the global pharmaceutical industry: the United States, the world's largest market, and Asia, a key region capturing an increasing share of global investment.

In the United States, the integration of DynamixE enhances the Group's technical capabilities and its ability to deliver complex industrial projects. Founded in New York in 2017 and established in major U.S. biopharmaceutical hubs, the company has built a strong reputation as a methodological leader through its comprehensive Commissioning, Qualification & Validation (CQV) programs and its recognized expertise in process engineering and automation



"The integration of DynamixE accelerates our U.S. trajectory, already driven by strong growth momentum in the region. It reinforces our footprint in the United States and clearly reflects our ambition to become a leading player in this market," **said Mathieu Roger, CEO and Founder of Efor.**

In Asia, the addition of No deviation is designed to further strengthen the Group's regional foothold, which has already grown significantly in recent months. Based in Singapore, a major regional hub, the company reinforces Efor's presence across Asia. With more than 300 employees now operating in the region, the Group is strengthening its position in key Asian markets, particularly China.

"Asia is a strategic pillar of our global development. With No deviation, we are consolidating our leadership in Singapore and accelerating our expansion across the continent. Asia is a strategic market, and we intend to strengthen our presence there over the long term," **added the Group's CEO.**

A Clear Global Ambition

Since its founding in Lyon in 2013, Efor has experienced rapid growth, combining organic expansion with targeted acquisitions. With more than 3,000 employees and operations in 18 countries, the Group supports 90% of the global leaders in the pharmaceutical sector and generated €340 million in revenue in 2025.

Following the successive integrations of PharmEng Technology, Project Delivery Partners (PDP), and Process Engineering Specialists (PES) in 2025, Efor now operates with a global organization supported by a strong local footprint. This hybrid model — combining agility and proximity with the strength of a structured international player — represents a distinctive positioning and enables the Group to respond quickly to strategic industrial investment projects.

Its strategy is to establish the Group sustainably among the global leaders in quality and compliance by strengthening its presence in the world's main industrial hubs, where production capacity and therapeutic innovation are concentrated.

A Value Proposition at the Heart of Industry Transformation

The Life Sciences sector is undergoing profound transformation. The rise of biotherapies, the expansion of manufacturing capacity, and increasingly stringent regulatory requirements are redefining industrial standards.

In this environment, reliability and speed of industrial commissioning have become critical. Efor supports manufacturers in securing their infrastructure, anticipating regulatory constraints, and accelerating access to safe treatments. The Group operates at the very heart of major international laboratories' facilities, helping transform scientific innovation into compliant and fully operational production capabilities.

By strengthening its presence simultaneously in North America and Asia - alongside Europe, the historical foundation of its development - Efor is consolidating a structured global footprint and reaffirming its ability to operate at the center of the world's largest industrial investments.

About Efor Group

Founded in 2013, Efor Group is now a leading international player specializing in quality and regulatory compliance for the healthcare industries. With more than 3,000 employees across 18 countries, the Group supports global leaders in the pharmaceutical, biotechnology, and medical device sectors in ensuring the compliance of their manufacturing sites and accelerating the delivery of innovative therapeutic solutions to patients.

Its mission is to remove technical and regulatory barriers so that innovation can reach patients faster, under the highest standards of safety and reliability.

Committed to becoming a global leader while remaining true to its founding values, Efor Group fully integrates social and environmental priorities into its operations. Through concrete initiatives that support society, sustainability, and innovation, the Group pursues a long-term growth vision guided by excellence, commitment, and collaboration.

efor.com

About DynamixE, Inc

Founded in 2017 and headquartered in New York, DynamixE, Inc. is a technology company specializing in biomanufacturing facility projects. The firm provides end-to-end support across Commissioning, Qualification & Validation (CQV), process engineer and automation.

DynamixE partners with leading pharmaceutical and biotechnology organizations to deliver complex biomanufacturing projects. Recognized for its technical rigor, execution excellence, and client-focused approach, the company is driven by a culture rooted in precision, accountability, and continuous improvement. DynamixE is committed to delivering mission-critical facilities that meet the highest standards of quality, regulatory compliance, and operational performance.

About No deviation

Founded in 2007, No deviation is a consulting firm supporting pharmaceutical and biotechnology companies in delivering compliant, efficient, and high-quality operations. Active across Asia and Europe, the company provides end-to-end support throughout the project lifecycle, including engineering consultancy, Commissioning, Qualification & Validation (CQV), quality and regulatory compliance, and project management.

No deviation applies lean, risk-based methodologies aligned with international standards such as GAMP 5, Annex 15, ASTM E2500, and ICH Q9. Its expertise spans audit readiness, QMS remediation, documentation support, operational readiness, and vendor coordination.
Among its strategic collaborations, the partnership with Fedegari has contributed to reinforcing its capabilities in sterilization-related qualification and validation projects.
Driven by a strong commitment to patient safety and operational excellence, No deviation works side-by-side with client teams to deliver practical, sustainable solutions that enhance compliance, efficiency, and performance across regulated environments.

nodeviation.com

Press Contact

Floriane CARRET

+33 6 89 42 79 02

floriane.carret@efor-group.com

The Arcane - Hanaé Plassard

+33 6 72 08 30 18

h.plassard@the-arcane.com

Investment team and advisors involved in the transaction:

Investors

- **RAISE Invest**
  - Mathieu Blanc
  - Aymeric Marraud des Grottes
  - Maud Nivelle
  - Paul Delannoy
- **Andera Acto**
  - Arnaud Faure
  - Antoine Soucaze
  - Antoine Guérillon
  - Anissa Peer
- **Investir pour l'Enfance**
- **CAPZA**
  - Guillaume de Jongh
  - Charles Devevey
  - Ombeline Danjoux

Legal Advisory

- **Agilys Avocats (No deviation)**
  - Baptiste Bellone
  - Carolle Thain-Navarro
  - Sophie Auvergne
- **Mayer Brown**
  - Patrick Teboul
  - Marion Minard
  - Antoine Buisson

DD Legal & Social & Corporate Advisory

- **DLA Piper**
  - Alex Roberts
  - Lindsay Borrell
  - MacKenzie Jordan

DD Finance

- **RSM**
  - Eric Fougedoire
  - Charles Tiran

DD Tax

- **Eight Advisory France (No Deviation)**
  - Guillaume Rembry
  - Jeremy Cosma
  - Maxence Linker
- **RSM (DynamixE)**
  - Aimée Iannotti